N-methyl-4-nitroaniline is a yellow, crystalline compound that has been studied for its potential applications in various fields. It can be synthesized via a nitration reaction of N-methylaniline, resulting in the introduction of a nitro group at the para position. This compound exhibits interesting optical properties and has been explored for its potential use in organic light-emitting diodes (OLEDs). Its electronic structure allows for efficient energy transfer and light emission, making it a promising candidate for OLED materials. Furthermore, N-methyl-4-nitroaniline has been investigated for its pharmacological activities, particularly as a potential anti-inflammatory agent. Its ability to modulate certain enzymes and signaling pathways suggests potential therapeutic applications. Due to its versatile properties, N-methyl-4-nitroaniline continues to be a subject of ongoing research, aiming to further understand its potential applications in various scientific and technological fields.'
N-methyl-4-nitroaniline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7483 |
| CHEMBL ID | 1329734 |
| SCHEMBL ID | 177790 |
| SCHEMBL ID | 12707572 |
| MeSH ID | M0552687 |
| Synonym |
|---|
| 4-nitro-n-methylaniline |
| n-methyl-4-nitroaniline |
| 100-15-2 |
| aniline, n-methyl-p-nitro- |
| n-methyl-p-nitraniline |
| nsc-5390 |
| p-(methylamino)nitrobenzene |
| nsc5390 |
| n-methyl-p-nitroaniline |
| n-monomethyl-p-nitroaniline |
| benzenamine, n-methyl-4-nitro- |
| p-nitro-n-methylaniline |
| NCGC00091370-01 |
| AC-907/25014172 |
| einecs 202-823-2 |
| ai3-08826 |
| nsc 5390 |
| inchi=1/c7h8n2o2/c1-8-6-2-4-7(5-3-6)9(10)11/h2-5,8h,1h |
| n-methyl-4-nitroaniline, 97% |
| smr001370918 |
| MLS002415758 |
| AKOS002312303 |
| A800059 |
| n-methyl-4-nitro-aniline |
| NCGC00091370-02 |
| unii-j836wlv9bw |
| ec 202-823-2 |
| j836wlv9bw , |
| HMS3039B06 |
| cas-100-15-2 |
| dtxcid605635 |
| tox21_200001 |
| NCGC00257555-01 |
| dtxsid7025635 , |
| M1011 |
| methyl(4-nitrophenyl)amine |
| FT-0629710 |
| PS-4951 |
| 4-(methylamino)nitrobenzene |
| n-methyl(4-nitrophenyl)amine |
| 4-methylamino-nitrobenzene |
| methyl-(4-nitro-phenyl)-amine |
| (4-nitro-phenyl)-methylamine |
| SCHEMBL177790 |
| CHEMBL1329734 |
| SCHEMBL12707572 |
| n-(4-nitrophenyl)-n-methylamine |
| n-methyl-n-(4-nitrophenyl)amine # |
| STR06194 |
| W-109374 |
| mfcd00007305 |
| n-methyl-4-nitrobenzenamine |
| nitronaniline |
| BCP04516 |
| CS-0011554 |
| AMY40126 |
| p-(n-methylamino)nitrobenzene |
| n-(4-nitrophenyl)-n-methylaniline |
| methyl-4-nitroaniline, n- |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 11.2202 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 40.0126 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 55.5831 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347399 |
| AR protein | Homo sapiens (human) | Potency | 13.6831 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743036; AID743040; AID743042; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 47.7664 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 54.5935 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.5414 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 77.1154 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 61.7731 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.5935 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 40.0560 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079; AID743080 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 4.4668 | 0.0237 | 23.2282 | 63.5986 | AID588543 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 54.5935 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 12.2220 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 5.5055 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.7731 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.3616 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 10.9850 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 5.4594 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 19.0115 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||